Atlantic Equities raised the price target for the Edwards Lifesciences Corporation (NYSE:EW) stock to “a Neutral”. The rating was released on April 15, 2021. The research report from Citigroup has downgraded the stock from Buy to Neutral, with a price target set at $97. The stock was reiterated by Canaccord Genuity, who disclosed in a research note on December 11, 2020, to Buy and set the price objective to $94.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of $0.54 during the last quarter as opposed to a consensus estimate of $0.47, which indicates the company beat its estimate by $0.07, which implies that the company surprised the market by 14.90%. It appears that the average earnings per share estimate for the current quarter (ending in Jun 2021) is $0.55. This is an average of 23 analysts’ earnings, where the high earnings per share estimate is $0.59 and the low earnings per share estimate is $0.5. According to 22 analyst estimates, an average revenue estimate of $1.28B is projected for the current quarter with a high revenue estimate of $1.31B and a low estimate of $1.23B.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Edwards Lifesciences Corporation (NYSE:EW) dipped -0.77% to close Friday’s market session at $95.52, lower as compared to yesterday’s close. The stock price fluctuated between $94.85 and $96.42 throughout the trading session with the volume trading being 2252708 shares, which represented a significant variation when compared to the three months average volume of 2.74 million shares. The firm’s stock price fluctuated -1.98% within the last five trades and 14.20% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 30.38% in the last 6 months and 15.67% was added to its value over the previous 3 months. EW stock is trading at a margin of 6.31%, 11.87% and 14.83% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, EW deals in the Healthcare domain. The stock is trading -2.64 percent below its 52-week high and 44.22 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 34.46. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Edwards Lifesciences Corporation’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 20.60 percent and the profit margin is 19.00 percent, and the company has reported a gross margin of 75.20 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $59.84 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Edwards Lifesciences Corporation (NYSE:EW) is 71.44. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 37.89. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 13.37 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 12.79, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.20 percent of Edwards Lifesciences Corporation shares are owned by insiders, and 87.30 percent are held by financial institutions. SELLERS ROBERT W.A., the VP, Corporate Controller at Edwards Lifesciences Corporation (EW) has sold 12,000 shares of firm on Apr 23 at a price of $97.66 against the total amount of $1.17 million. In another inside trade, STONE HEISZ LESLIE, Director of Edwards Lifesciences Corporation (NYSE:EW) sold 6,707 shares of the firm on Apr 23 for a total worth of $0.65 million at a price of $97.52. An inside trade which took place on Apr 22, CVP, Critical Care of Edwards Lifesciences Corporation Szyman Catherine M. sold 3,389 shares of firm against total price of $0.32 million at the cost of $94.40 per share.
How Edwards Lifesciences Corporation (EW) Stock Is Sustainable?
To Conclude, the score of Environmental, Social and Governance (ESG) has been traditionally used by investors to measure the actions of corporations and to make their future financial predictions. According to the ESG rating scale, there are five hazard levels in the scale: marginal, weak, moderate, high, and extreme. The next generation ESG score is a scale from 0 to 100 where 100 represents the most extreme situation. The score was designed to assist investors at safety and investment level in identifying and recognizing financially relevant ESG threats. A current assessment of the Edwards Lifesciences Corporation’s sustainability factors indicates that it scores at 18 or 18th percentile overall, with an Environment Score of 3 or 3 percentile, a Social Score of 9 or 9 percentile, and a Governance Score of 7 or 7 percentile.